Cyclacel Pharmaceuticals received GBP 2.3 million as a research & development tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYCC:
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
- Cyclacel Pharmaceuticals Appoints New Interim Chief Medical Officer
- Cyclacel Pharmaceuticals Announces Chief Medical Officer Termination
- Cyclacel terminates CMO Kirschbaum, appoints Schwartz as interim CMO
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
